Entering the ASX 200 should be a moment of celebration for any biotech start-up.
For Silvio Itescu, the multimillionaire founder and chief executive of stem cell group Mesoblast, it should be an even-greater triumph after a fourfold surge in the stock price spurred by an announcement that the company was assessing one of its drug candidates as a treatment for COVID-19 patients.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
Tom Richardson was a journalist at The Australian Financial Review
